Romiplostim N01 for Platelet Recovery After Haploidentical HSCT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Romiplostim N01 for Platelet Recovery After Haploidentical HSCT — Stella

Home/Acute Myeloid Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Acute Myeloid Leukemia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

Key details

Phase

Early testing

Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment target

~130 participants

Started

June 2025

Primary completion

December 2027

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.